Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
107.50 USD   +0.64%
11/22Merck & Co.'s Keytruda Combo Extends Survival in Late-stage Stomach Cancer Study
MT
11/22Merck to Acquire Imago BioSciences Inc
AQ
11/22Merck's Keytruda Meets Primary Endpoint in Phase 3 Trial of Keytruda in Gastric Cancer Patients
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

TME PHARMA ANNOUNCES UPCOMING PRESENTATION AT THE SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING 2022

09/21/2022 | 09:46am EST

Berlin - TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that new data from the ongoing Phase 1/2 GLORIA trial in brain cancer will be presented by Dr. Frank Giordano, the principal investigator of the study, in a poster presentation at the Society for Neuro-Oncology (SNO) Annual Meeting.

The meeting will take place in Tampa Bay, Florida, US from November 16 - 20, 2022.

TME Pharma N.V. Aram Mangasarian, Ph.D., CEO Bryan Jennings, CFO Tel. +49 (0) 30 726247 0 investors@tmepharma.com

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma's approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact.

In the GLORIA clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial is in discussion with regulatory authorities in the United States and Europe. The company's second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. TME Pharma is considering several solid tumors for further clinical development.

About the GLORIA Study

GLORIA (NCT04121455) is TME Pharma's dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab and C. radiotherapy and pembrolizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma's planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nabpaclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain 'forwardlooking statements.' Forward-looking statements are based on TME Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma's ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. 0.64% 107.5 Delayed Quote.40.27%
TME PHARMA N.V. -3.67% 2.8515 End-of-day quote.-87.81%
All news about MERCK & CO., INC.
11/22Merck & Co.'s Keytruda Combo Extends Survival in Late-stage Stomach Cancer Study
MT
11/22Merck to Acquire Imago BioSciences Inc
AQ
11/22Merck's Keytruda Meets Primary Endpoint in Phase 3 Trial of Keytruda in Gastric Cancer ..
MT
11/22Merck's Keytruda Hits Main Endpoint in Stomach Cancer Study
DJ
11/22Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in P..
BU
11/22Merck Announces Phase 3 Keynote-859 Trial Met Primary Endpoint of Overall Survival in P..
CI
11/21Merck & Co. To Buy Bone Marrow Disease-focused Imago BioSciences For $1.4 Billion
MT
11/21Sector Update: Health Care Stocks Advance Modestly
MT
11/21Trending : Merck to Acquire Imago BioSciences for $1.35 Billion
DJ
11/21Sector Update: Health Care Stocks Staying on Positive Ground
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 59 072 M - -
Net income 2022 14 812 M - -
Net Debt 2022 18 689 M - -
P/E ratio 2022 18,4x
Yield 2022 2,60%
Capitalization 273 B 273 B -
EV / Sales 2022 4,93x
EV / Sales 2023 4,86x
Nbr of Employees 67 500
Free-Float 70,8%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 107,50 $
Average target price 109,61 $
Spread / Average Target 1,96%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.40.27%272 555
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY30.95%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
ROCHE HOLDING AG-17.86%270 482